AURX
Nuo Therapeutics, Inc.
Next earnings Jul 29, 2026 · consensus $-0.01 EPS, $1.23M rev
Last earnings +8.0% on 2026-05-14
$1.01
▲ 0.00%$1.01▼ -32.67%
over 1Y
L $0.90EODHDH $3.23
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+11.6%
1M+2.0%
3M-29.9%
YTD-49.5%
1Y-32.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Revenue grew 142.7% YoY; but unprofitable (net margin -75.8%).
Revenue (FY2025) $3.31M · FY2025
Nuo Therapeutics, Inc. shows $3.31M in FY2025 revenue (+142.7% YoY), a -75.8% net margin, and 262.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $112K | $609K | $1.37M | $3.31M |
| Gross profit | $0.00 | $93.0K | $482K | $1.06M | $2.22M |
| Operating income | -$90.7K | -$3.32M | -$3.17M | -$2.46M | -$2.52M |
| Net income | -$90.7K | -$3.17M | -$3.17M | -$2.32M | -$2.51M |
| Diluted EPS | -$0.03 | — | — | — | — |
| Net margin | — | -2825.6% | -521.2% | -170.2% | -75.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$48.2M
EV / EBITDA—
EV / Sales14.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-5.2%
FCF yield-2.3%
Quality & risk
ROIC (est.)—
Free cash flow-$1.14M
Total debt$0.00
Net cash$549K
Altman Z-Score-18.59 distress
Piotroski F-Score3/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+3.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-052026-06-05open ↗SCHEDULE 13D/AFiling2026-06-03open ↗8-KPeriod ending 2026-05-292026-06-03open ↗4Period ending 2026-05-292026-06-02open ↗4/APeriod ending 2026-01-232026-06-02open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-QPeriod ending 2026-03-312026-05-14open ↗10-KPeriod ending 2025-12-312026-03-30open ↗SCHEDULE 13G/AFiling2026-02-12open ↗4Period ending 2026-01-232026-01-26open ↗SCHEDULE 13D/AFiling2026-01-26open ↗8-KPeriod ending 2026-01-212026-01-26open ↗
Frequently asked
- Is Nuo Therapeutics, Inc. (AURX) a buy?
- AURX currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 142.7% YoY; but unprofitable (net margin -75.8%).
- What is Nuo Therapeutics, Inc.'s quality score?
- AURX scores 34.23529411764706/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001091596, latest 10-Q filed 2026-05-14) · EODHD · as of 6/22/2026, 11:31:27 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.